Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person FLT3 D839G [plasma membrane]

Class:Id	EntityWithAccessionedSequence:9695718
_displayName	FLT3 D839G [plasma membrane]
_timestamp	2020-07-15 14:55:07
compartment	[Compartment:876] plasma membrane
created	[InstanceEdit:9695711] Rothfels, Karen, 2020-07-15
crossReference	[DatabaseIdentifier:9695681] COSMIC:COSV54045448 [DatabaseIdentifier:9695695] COSMIC:COSM4606330
disease	[Disease:1500689] cancer [Disease:2317476] acute lymphocytic leukemia [Disease:9630839] acute myeloid leukemia
endCoordinate	993
hasModifiedResidue	[ReplacedResidue:9695636] L-aspartic acid 839 replaced with glycine
literatureReference	[LiteratureReference:9695648] Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
name	FLT3 D839G STK-1
referenceEntity	[ReferenceGeneProduct:54914] UniProt:P36888 FLT3 [Homo sapiens]
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9695729] R-HSA-9695718.1
startCoordinate	27
(hasComponent)	[Complex:9695763] FLT3 D839G dimer [plasma membrane] [Homo sapiens]
(hasMember)	[CandidateSet:9682396] kinase domain mutants of FLT3 [plasma membrane] [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by FLT3 D839G [plasma membrane] (9695718)